First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Pneumologie | October 26, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1055/s-0041-1723293